Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.59 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.59 |
| ▸ | GNG2 | P59768 | 1/20 | 0.49 |
| ▸ | GNB1 | P62873 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4960577 | 0.85 | MAPT (0.62) | MAPTMEN1KMT2ATDP1FTO | |
| SCHEMBL31620935 | 0.84 | MAPT (0.71) | MAPTMEN1KMT2ATDP1FTO | |
| Fluorescein SCHEMBL27917033 | 0.81 | FTO (0.67) | MAPTMEN1KMT2ATDP1FTO | |
| SCHEMBL4959116 | 0.80 | LMNA (0.64) | MAPTMEN1KMT2ATDP1GNG2 | |
| SCHEMBL29367262 | 0.79 | MAPT (0.64) | MAPTMEN1KMT2ATDP1FTO | |
| SCHEMBL499184 | 0.79 | MAPT (0.64) | MAPTMEN1KMT2ATDP1FTO | |
| SCHEMBL499135 | 0.79 | MAPT (0.64) | MAPTMEN1KMT2ATDP1FTO | |
| Dichlorofluorescein SCHEMBL30606648 | 0.79 | MAPT (0.64) | MAPTMEN1KMT2ATDP1FTO | |
| SCHEMBL408340 | 0.79 | MAPT (0.64) | MAPTMEN1KMT2ATDP1FTO | |
| SCHEMBL30218785 | 0.79 | MAPT (0.64) | MAPTMEN1KMT2ATDP1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118215417-A | Antibacterial multi-layer fabric medium and preparation method thereof | 乔治华盛顿大学 | 2024-06-18 | — | — | CN | disclosed |
| CN-112368027-A | Absorbent biophotonic fiber systems | 克洛克斯科技公司 | 2021-02-12 | — | — | CN | disclosed |
| US-10130706-B2 | Biophotonic materials and uses thereof | KLOX TECHNOLOGIES INC. (CA) | 2018-11-20 | — | — | US | disclosed |
| CN-108066896-A | Phototherapy device and method | 克洛克斯科技公司 | 2018-05-25 | — | — | CN | disclosed |
| CN-107669507-A | Bio-photon composition, kit and method | 克洛克斯科技公司 | 2018-02-09 | — | — | CN | disclosed |
| CN-104379213-B | Phototherapy device and method | 克洛克斯科技公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-104394888-A | Compositions and methods for biophotonic bone reconstruction | KLOX TECHNOLOGIES INC | 2015-03-04 | — | — | CN | disclosed |
| CN-104379213-A | Phototherapy device and method | KLOX TECHNOLOGIES INC | 2015-02-25 | — | — | CN | disclosed |
| US-20090192209-A1 | Extended treatment of tumors through vessel occlusion with light activated drugs | LIGHT SCIENCES ONCOLOGY, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-7060695-B2 | Method to prevent vision loss | QLT, INC. (CA) | 2006-06-13 | — | — | US | disclosed |
| US-20060039965-A1 | Drug delivery system for hydrophobic drugs | QLT INC. (CA) | 2006-02-23 | — | — | US | disclosed |
| US-6599891-B2 | Administering to the subject an amount of a photosensitizer (PS) sufficient to allow said photosensitizer to localize in lesion; irradiating said lesion with light having a wavelength absorbed by said PS | QLT INC. (CA) | 2003-07-29 | — | — | US | disclosed |
| US-20020183302-A1 | Method to prevent vision loss | TECHNOLAS PERFECT VISION GMBH (DE) | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183302-A1 | Method to prevent vision loss | VEGFA, ALDH1A2, PDE6C | MAPT 2446/4885MEN1 3014/4885KMT2A 3251/4885 |
| US-20090192209-A1 | Extended treatment of tumors through vessel occlusion with light activated drugs | PTGIR, TEK, FLT4 | MAPT 2414/4885MEN1 1206/4885KMT2A 3558/4885 |
| US-20060039965-A1 | Drug delivery system for hydrophobic drugs | LIPA, ABCG2, NSF | MAPT 437/4885MEN1 1835/4885KMT2A 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.